The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Open accessAbstract
The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results on a novel checkpoint inhibitor, NKG2A. This receptor is expressed on cytotoxic lymphocytes, including NK cells and subsets of activated CD8+ T cells. Blocking antibodies to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial. Monalizumab is inhibiting this checkpoint in human beings and future clinical trials will have to reveal its potency in combination with other cancer treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
NK cell heparanase controls tumor invasion and immune surveillance
Putz, E. M., Mayfosh, A. J., Kos, K., Barkauskas, D. S., Nakamura, K., Town, L., Goodall, K. J., Yee, D. Y., Poon, I. K. H., Baschuk, N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92958 · Cited by 105
RetractedPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Self-citationTumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
Self-citationMarincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Self-citationKathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Self-citationMamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Self-citationTissue-Resident T Cells and Other Resident Leukocytes
Masopust, D., & Soerens, A. G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053214 · Cited by 608
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition
Pereira, B. I., Devine, O. P., Vukmanovic-Stejic, M., Chambers, E. S., Subramanian, P., Patel, N., Virasami, A., Sebire, N. J., Kinsler, V., Valdovinos, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10335-5 · Cited by 556
Béziat, V., Liu, L. L., Malmberg, J.-A., Ivarsson, M. A., Sohlberg, E., Björklund, A. T., Retière, C., Sverremark-Ekström, E., Traherne, J., Ljungman, P., et al. (2013) · Blood · doi:10.1182/blood-2012-10-459545 · Cited by 512
Lee, N., Goodlett, D. R., Ishitani, A., Marquardt, H., & Geraghty, D. E. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.4951 · Cited by 505
Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490
Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
Hombrink, P., Helbig, C., Backer, R. A., Piet, B., Oja, A. E., Stark, R., Brasser, G., Jongejan, A., Jonkers, R. E., Nota, B., et al. (2016) · Nature Immunology · doi:10.1038/ni.3589 · Cited by 455
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 439
Self-citationNK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01451-3 · Cited by 376
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 342
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 333
Self-citationAnalysis of regulatory CD8 T cells in Qa-1-deficient mice
Hu, D., Ikizawa, K., Lu, L., Sanchirico, M. E., Shinohara, M. L., & Cantor, H. (2004) · Nature Immunology · doi:10.1038/ni1063 · Cited by 330
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., Bando, J. K., Kim, A. H., Walker, J., Andahazy, M., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.037 · Cited by 280
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
The role of cytokines in the regulation of NK cells in the tumor environment
Konjević, G. M., Vuletić, A. M., Mirjačić Martinović, K. M., Larsen, A. K., & Jurišić, V. B. (2019) · Cytokine · doi:10.1016/j.cyto.2019.02.001 · Cited by 279
HLA class I antigen abnormalities and immune escape by malignant cells
Seliger, B., Cabrera, T., Garrido, F., & Ferrone, S. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0404 · Cited by 270
de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Natanov, R., Putter, H., Smit, V. T. H. B. M., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J. H., & Kuppen, P. J. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002629 · Cited by 266
Le Dréan, E., Vély, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal, G., Gervois, N., Moretta, A., Jotereau, F., & Vivier, E. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<264::aid-immu264>3.0.co;2-o · Cited by 254
Self-citationTargeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Self-citationClass I HLA haplotypes form two schools that educate NK cells in different ways
Horowitz, A., Djaoud, Z., Nemat-Gorgani, N., Blokhuis, J., Hilton, H. G., Béziat, V., Malmberg, K.-J., Norman, P. J., Guethlein, L. A., & Parham, P. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1672 · Cited by 225
Self-citationGlasner, A., Levi, A., Enk, J., Isaacson, B., Viukov, S., Orlanski, S., Scope, A., Neuman, T., Enk, C. D., Hanna, J. H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.007 · Cited by 222
CD94-NKG2A receptors regulate antiviral CD8+ T cell responses
Moser, J. M., Gibbs, J., Jensen, P. E., & Lukacher, A. E. (2002) · Nature Immunology · doi:10.1038/ni757 · Cited by 220
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes
Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. B., van der Burg, S. H., Nijman, H., & van Hall, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100354108 · Cited by 215
Self-citationZemek, R. M., De Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S. J., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 212
Structural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E
O'Callaghan, C. A., Tormo, J., Willcox, B. E., Braud, V. M., Jakobsen, B. K., Stuart, D. I., McMichael, A. J., Bell, J. I., & Jones, E. Y. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80053-2 · Cited by 205
Mehta, A. M., Jordanova, E. S., Kenter, G. G., Ferrone, S., & Fleuren, G. J. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0362-8 · Cited by 192
Piet, B., de Bree, G. J., Smids-Dierdorp, B. S., van der Loos, C. M., Remmerswaal, E. B. M., von der Thüsen, J. H., van Haarst, J. M. W., Eerenberg, J. P., ten Brinke, A., van der Bij, W., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44675 · Cited by 183
Malmberg, K.-J., Levitsky, V., Norell, H., Matos, C. T. D., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15564 · Cited by 180
Analysis of HLA-E expression in human tumors
Marín, R., Ruiz-Cabello, F., Pedrinaci, S., Méndez, R., Jiménez, P., Geraghty, D. E., & Garrido, F. (2003) · Immunogenetics · doi:10.1007/s00251-002-0526-9 · Cited by 178
Erratum: Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.110 · Cited by 167
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells
Ramsuran, V., Naranbhai, V., Horowitz, A., Qi, Y., Martin, M. P., Yuki, Y., Gao, X., Walker-Sperling, V. E. K., Prete, G. Q. D., Schneider, D. K., et al. (2018) · Science · doi:10.1126/science.aam8825 · Cited by 156
Self-citationViant, C., Fenis, A., Chicanne, G., Payrastre, B., Ugolini, S., & Vivier, É. (2014) · Nature Communications · doi:10.1038/ncomms6108 · Cited by 155
NKG2A is a NK cell exhaustion checkpoint for HCV persistence
Zhang, C., Wang, X., Li, S.-R., Twelkmeyer, T., Wang, W., Zhang, S.-Y., Wang, S., Chen, J., Jin, X., Wu, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09212-y · Cited by 154
Sheu, B., Chiou, S., Lin, H., Chow, S., Huang, S., Ho, H., & Hsu, S.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2108 · Cited by 141
Yazdi, M. T., van Riet, S., van Schadewijk, A. M., Fiocco, M. F., van Hall, T., Taube, C., Hiemstra, P. S., & van der Burg, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.6506 · Cited by 105
Hamid, M. A., Wang, R., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado‐Pérez, D., Waugh, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0885 · Cited by 98
Epigenetic regulation of differentialHLA-Aallelic expression levels
Ramsuran, V., Kulkarni, S., Ó’hUigín, C., Yuki, Y., Augusto, D. G., Gao, X., & Carrington, M. N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv158 · Cited by 97
Gustafson, K. S., & Ginder, G. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.20035 · Cited by 87
The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress.
van Hall, T., Oliveira, C., Joosten, S., & Ottenhoff, T. (2010) · Microbes and infection · doi:10.1016/j.micinf.2010.07.011 · Cited by 74
Andersson, E. K., Poschke, I. C., Villabona, L. E. E., Carlson, J. W., Lundqvist, A., Kiessling, R. W., Seliger, B., & Masucci, G. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052213 · Cited by 73
Derré, L., Corvaisier, M., Pandolfino, M., Diez, E., Jotereau, F., & Gervois, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4864 · Cited by 65
Hallner, A., Bernson, E., Hussein, B. A., Sander, F. E., Brune, M. L., Aurelius, J., Martner, A., Hellstrand, K., & Thorén, F. B. (2019) · Blood · doi:10.1182/blood-2018-09-874990 · Cited by 65
Zhou, J., Matsuoka, M., Cantor, H., Homer, R., & Enelow, R. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.25 · Cited by 62
A Structural Basis for Antigen Presentation by the MHC Class Ib Molecule, Qa-1b
Li, Z., Sullivan, L. C., Vivian, J. P., Walpole, N. G., Harpur, C. M., Rossjohn, J., Clements, C. S., & Brööks, A. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102379 · Cited by 57
van Esch, E. M. G., Tummers, B., Baartmans, V., Osse, E. M., ter Haar, N. T., Trietsch, M. D., Hellebrekers, B. W. J., Holleboom, C. A. G., Nagel, H., Tan, L. T., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28713 · Cited by 46
Gunturi, A., Berg, R. E., Crossley, E. C., Murray, S. E., & Forman, J. (2005) · European Journal of Immunology · doi:10.1002/eji.200425735 · Cited by 45
Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes
Ramsuran, V., Hernández‐Sánchez, P. G., Ó’hUigín, C., Sharma, G., Spence, N., Augusto, D. G., Gao, X., García-Sepúlveda, C. A., Kaur, G., Mehra, N. K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601679 · Cited by 45
Hiraki, A., Fujii, N., Murakami, T., Kiura, K., Aoe, K., Yamane, H., Masuda, K., Maeda, T., Sugi, K., Darżynkiewicz, Z., et al. (2004) · PubMed · Cited by 23
Yunis, E. J., Romero, V. A., Diaz‐Griffero, F., Zúñiga, J., & Koka, P. S. (2007) · PubMed · Cited by 20
Cited by
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
“Monalizumab is a humanized IgG4 NKG2A-blocking antibody which has been administered in phase 2 clinical trials.(85) Monalizumab monotherapy has limited efficacy in a cohort of twenty-six HNSCC patients.”
BackgroundThe NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Metadata
- Authors
- van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., Narni-Mancinelli, E., van der Burg, S. H., & Vivier, E.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-10-17
- Volume
- 7
- Issue
- 1
- Pages
- 263-263
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W2981056570
- Cited by
- 292
- References
- 82
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.